New Report by Mercy For Animals: McDonald's Serves Plant-Based Burgers Abroad. Why Not in America?

Mercy For Animals gave McDonald’s 1 out of 30 points in its review of plant-based burger offerings, placing it in the lowest tier for lacking a U.S. plant-based burger option. The report found that 6 of 25 evaluated chains (24%) offer a dedicated plant-based patty on their primary U.S. menus and said 71% of U.S. consumers are open to eating plant-based foods. It called on McDonald’s to expand U.S. choices, citing its existing plant-based offerings in the UK and Ireland; no market reaction was reported.

Analysis

This is an advocacy signal, not evidence of incremental demand or a near-term earnings change. For MCD, a U.S. plant-based launch would be an execution decision: it could add menu relevance among flexitarians, but also risks slower throughput, extra kitchen complexity, and cannibalization rather than genuinely incremental orders. The report’s consumer-attitude statistic does not establish purchase frequency, willingness to pay, or profitable repeat demand. Any beef-sourcing impact would likely require broad adoption before becoming material; do not translate the campaign into an immediate commodity or margin call. WEN is cited only as a peer with limited U.S. plant-based availability, so the report creates little company-specific read-through beyond shared reputational exposure.

Days: likely limited fundamental impact absent a company response. Over 1–3 months, the useful catalyst is whether MCD tests or announces a U.S. product and provides evidence on trial, repeat purchase, price, and operational performance—not the report score itself. Over 6–18 months, a successful rollout could support customer engagement and modestly pressure beef mix, while failed trials could reinforce the view that U.S. demand is not commercially compelling. Contrarian read: the campaign may overstate addressable demand by conflating openness with purchasing; conversely, investors may underweight option value if MCD can reuse international product experience. Falsify the low-impact view with a scaled U.S. rollout and disclosed evidence of incremental sales or repeat demand; falsify the adoption thesis with weak trial-to-repeat conversion, menu withdrawal, or management citing poor unit economics.

Key Decisions for Investors

• No trade on the report alone; its score is not a sales or earnings data point, and there is no clear basis for a MCD/WEN pair from this evidence.
• Treat MCD as a watch item: reassess only on a U.S. test or launch, looking for price point, store coverage, repeat-purchase data, incremental versus substituted orders, and any operational or sourcing commentary.
• Monitor WEN for an independent menu or demand catalyst rather than treating its inclusion in the report as a new negative fundamental signal.